![](/wp-content/uploads/2024/07/Screenshot-2024-07-01-at-4.37.19%E2%80%AFPM.png)
$599
BI Announces Triple Agonist for Obesity Treatment; Merck Initiates Ph2a Trial of Efinopegdutide in MASLD
Two cardiometabolic-related news items have been observed: Boehringer Ingelheim and Gubra announced the launch of a Ph1 trial evaluating its triple agonist, BI 3034701, in obesity (view press release); and Merck initiated a Ph2a trial evaluating Q2W vs. QW administration of efinopegdutide (MK-6024) in MASLD (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including thoughts on potential MOAs for BI’s triple agonist.